Monomethyl auristatin antibody and peptide drug conjugates for trimodal cancer chemo-radio-immunotherapy
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Monomethyl auristatin antibody and peptide drug conjugates for trimodal cancer chemo-radio-immunotherapy
Authors
Keywords
-
Journal
Nature Communications
Volume 13, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-07-05
DOI
10.1038/s41467-022-31601-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cooperative targeting of immunotherapy-resistant melanoma and lung cancer by an AXL-targeting antibody-drug conjugate and immune checkpoint blockade
- (2021) Julia Boshuizen et al. CANCER RESEARCH
- Unlocking the potential of antibody–drug conjugates for cancer therapy
- (2021) Joshua Z. Drago et al. Nature Reviews Clinical Oncology
- Tumor Activated Cell Penetrating Peptides to Selectively Deliver Immune Modulatory Drugs
- (2021) Dina V. Hingorani et al. Pharmaceutics
- Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
- (2021) Nancy Y Lee et al. LANCET ONCOLOGY
- Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial
- (2021) Evan Y Yu et al. LANCET ONCOLOGY
- The clinical development of antibody–drug conjugates — lessons from leukaemia
- (2021) Elias Jabbour et al. Nature Reviews Clinical Oncology
- Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer
- (2021) Zhiyong Wang et al. Nature Communications
- Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer
- (2021) Pasi A. Janne et al. Cancer Discovery
- Using Preclinical Data to Design Combination Clinical Trials of Radiation Therapy and Immunotherapy
- (2020) Michael J. Gough et al. SEMINARS IN RADIATION ONCOLOGY
- Redirecting extracellular proteases to molecularly guide radiosensitizing drugs to tumors
- (2020) Dina V. Hingorani et al. BIOMATERIALS
- Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody–Drug Conjugate
- (2020) Mark G. Anderson et al. MOLECULAR CANCER THERAPEUTICS
- Acquired Resistance to Antibody-Drug Conjugates
- (2019) Denis Collins et al. Cancers
- Antibody-Drug Conjugate-Based Therapeutics: State of the Science
- (2019) Michael J Birrer et al. JNCI-Journal of the National Cancer Institute
- Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long‐term survival follow‐up from the randomized, phase 3 INO‐VATE study
- (2019) Hagop M. Kantarjian et al. CANCER
- Antibody–Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index
- (2019) Steven Coats et al. CLINICAL CANCER RESEARCH
- Antibody–drug conjugates for cancer
- (2019) Cindy H Chau et al. LANCET
- Precision Chemoradiotherapy for HER2 Tumors Using Antibody Conjugates of an Auristatin Derivative with Reduced Cell Permeability
- (2019) Dina V. Hingorani et al. MOLECULAR CANCER THERAPEUTICS
- Automated optimized parameters for T-distributed stochastic neighbor embedding improve visualization and analysis of large datasets
- (2019) Anna C. Belkina et al. Nature Communications
- Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer
- (2019) Francis W. Hunter et al. BRITISH JOURNAL OF CANCER
- U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation
- (2019) Koji Haratani et al. JOURNAL OF CLINICAL INVESTIGATION
- Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non–Small-Cell Lung Cancer
- (2019) Jeffrey D. Bradley et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
- (2019) Shanu Modi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Syngeneic animal models of tobacco-associated oral cancer reveal the activity of in situ anti-CTLA-4
- (2019) Zhiyong Wang et al. Nature Communications
- Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology
- (2018) Robert G Bristow et al. LANCET ONCOLOGY
- Matrix Metalloproteinase Inhibitors in Cancer Therapy: Turning Past Failures Into Future Successes
- (2018) Arthur Winer et al. MOLECULAR CANCER THERAPEUTICS
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- Immunological Mechanisms Responsible for Radiation-Induced Abscopal Effect
- (2018) María E. Rodríguez-Ruiz et al. TRENDS IN IMMUNOLOGY
- Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
- (2018) Spencer C. Wei et al. Cancer Discovery
- Clinical Development of Novel Drug–Radiotherapy Combinations
- (2018) Saif S. Ahmad et al. CLINICAL CANCER RESEARCH
- Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial
- (2018) Maura L Gillison et al. LANCET
- Radiotherapy induces responses of lung cancer to CTLA-4 blockade
- (2018) Silvia C. Formenti et al. NATURE MEDICINE
- Mouse Models for Cancer Immunotherapy Research
- (2018) Brian Olson et al. Cancer Discovery
- Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads
- (2017) Joanna C. Masters et al. INVESTIGATIONAL NEW DRUGS
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- (2017) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC
- (2017) Diego Alvarado et al. PLoS One
- DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity
- (2017) Claire Vanpouille-Box et al. Nature Communications
- Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial
- (2016) Sergio Amadori et al. JOURNAL OF CLINICAL ONCOLOGY
- Antibody–drug conjugates for cancer therapy
- (2016) Anish Thomas et al. LANCET ONCOLOGY
- A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor Response
- (2016) Z. Xiao et al. MOLECULAR CANCER THERAPEUTICS
- Clinical development of new drug–radiotherapy combinations
- (2016) Ricky A. Sharma et al. Nature Reviews Clinical Oncology
- Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize
- (2016) Stephen R. Adams et al. Nature Communications
- Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery
- (2016) Suzanne I.S. Mosely et al. Cancer Immunology Research
- Tumor Radiosensitization by Monomethyl Auristatin E: Mechanism of Action and Targeted Delivery
- (2015) L. Buckel et al. CANCER RESEARCH
- Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy
- (2015) Andrew B Sharabi et al. LANCET ONCOLOGY
- Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study
- (2015) Maria Corinna A Palanca-Wessels et al. LANCET ONCOLOGY
- Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
- (2015) Christina Twyman-Saint Victor et al. NATURE
- Strategies for optimizing the response of cancer and normal tissues to radiation
- (2013) Everett J. Moding et al. NATURE REVIEWS DRUG DISCOVERY
- New Paradigms and Future Challenges in Radiation Oncology: An Update of Biological Targets and Technology
- (2013) S. L. Liauw et al. Science Translational Medicine
- Real-time In Vivo Molecular Detection of Primary Tumors and Metastases with Ratiometric Activatable Cell-Penetrating Peptides
- (2012) E. N. Savariar et al. CANCER RESEARCH
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Understanding resistance to EGFR inhibitors—impact on future treatment strategies
- (2010) Deric L. Wheeler et al. Nature Reviews Clinical Oncology
- Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
- (2010) Anas Younes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting Mammalian Target of Rapamycin by Rapamycin Prevents Tumor Progression in an Oral-Specific Chemical Carcinogenesis Model
- (2009) R. Czerninski et al. Cancer Prevention Research
- In vivo characterization of activatable cell penetrating peptides for targeting protease activity in cancer
- (2009) Emilia S. Olson et al. Integrative Biology
- Novel Peptide Linkers for Highly Potent Antibody−Auristatin Conjugate
- (2008) Svetlana O. Doronina et al. BIOCONJUGATE CHEMISTRY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation